
Common Cold - Pipeline Insight, 2024
Description
Common Cold - Pipeline Insight, 2024
DelveInsight’s, ''Common Cold - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Common Cold pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Common colds, or simply “colds,” are usually quite harmless and go away again on their own. The symptoms of a cold such as a cough, sore throat and a runny nose can be really annoying. A severe cold can make you feel weak and ill, too. Colds usually go away on their own after about a week, but some symptoms may last longer. Although a sore throat or a stuffy nose may be gone after just a few days, it can sometimes take up to three weeks for a cough to disappear completely. Treatment with medication usually isn’t necessary. Some medications may, at best, help relieve the symptoms a bit. Because colds are typically caused by viruses, it also doesn't make sense to use antibiotics to treat an ordinary cold. Antibiotics only fight bacteria.
Colds usually take a few days to fully develop. Typical symptoms include a stuffy or runny nose, sneezing, coughing and a sore throat. Sometimes a cold is also accompanied by a mild fever, weakness, a headache and joint pain. Occasionally, colds are mistaken for the flu. But flu symptoms are usually much worse. Also, a flu doesn't develop gradually. Instead, it generally starts very suddenly with a high fever, chills, and aching muscles and joints.
""Common Cold - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Common Cold pipeline landscape is provided which includes the disease overview and Common Cold treatment guidelines. The assessment part of the report embraces, in depth Common Cold commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Common Cold collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Common Cold. The therapies under development are focused on novel approaches to treat/improve Common Cold.
XC-8: EURRUS Biotech
EURRUS Biotech is developing histamine glutarimide, for the treatment of asthma, common cold and other acute respiratory viral infections. The Phase II study results show XC-8 as a highly effective, oral product with no side effects. The goal of XC-8 is the long-term use with mild and moderate asthma conditions to reduce patients' corticosteroid consumption
Further product details are provided in the report……..
Common Cold: Therapeutic Assessment
This segment of the report provides insights about the Common Cold drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Common Cold
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Common Cold: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Common Cold therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Common Cold drugs.
Common Cold Report Insights
- Common Cold Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Common Cold drugs?
- How many Common Cold drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Common Cold?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Common Cold therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Common Cold and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sanotize Research and Development
- Orbis Biosciences
- Exscientia
- EURRUS Biotech
- Nitric oxide
- Guaifenesin extended release
- ORB 110
- IMP 1088
- XC8
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Common Cold: Overview
- What is Common Cold?
- Types of Common Cold
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Common Cold– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- XC8: EURRUS Biotech
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- ORB 110: Orib Biosciences
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Common Cold Key Companies
- Common Cold Key Products
- Common Cold- Unmet Needs
- Common Cold- Market Drivers and Barriers
- Common Cold- Future Perspectives and Conclusion
- Common Cold Analyst Views
- Common Cold Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.